~~<i id='EFAD3EB5D1'><strike id='EFAD3EB5D1'><tt id='EFAD3EB5D1'><pre id='EFAD3EB5D1'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：comprehensive 2025-09-27 17:21:15 Page View：6824

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： US judge blocks portions of new Florida elections law
Next article： Activists slam private health insurers over coverage restrictions

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Bacterial infection may be ‘key event’ in endometriosis, study says

AnewstudydocumentshowFusobacteriummightspurthedevelopmentofendometriosis.V.R.Dowell/CDCEndometriosis

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

PhRMA sues HHS over Medicare drug price negotiation

PhRMAissuingtheBidenadministrationoveritsnewMedicaredrugpricenegotiationprogram.GraemeSloan/SipaUSAW